UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(AMENDMENT NO. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 11, 2015
Applied DNA Sciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of |
001-36745 (Commission File Number) |
59-2262718 (IRS Employer No.) |
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of principal executive offices; zip code)
Registrant’s telephone number, including area code:
631-240-8800
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
This Amendment No. 1 to Current Report on Form 8-K/A amends the Current Report on Form 8-K (the “Original Form 8-K”) of Applied DNA Sciences, Inc. (“we,” “us”, "APDN" or the “Company”), filed on September 17, 2015, regarding the Company’s announcement that it had entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Vandalia Research, Inc., a West Virginia corporation (now known as VR Holdings, Inc., “Vandalia”), and Derek A. Gregg, Vandalia’s Chief Executive Officer and a director of Vandalia, providing for the purchase by the Company of substantially all the assets ("Asset Acquisition") of Vandalia as of September 11, 2015. The Asset Purchase Agreement has been previously filed as Exhibit 2.1 to the Original Form 8-K. This Current Report on Form 8-K/A is being filed to provide certain audited financial statements and certain unaudited pro forma information required by Item 9.01 of Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
The audited consolidated balance sheets of Vandalia as of December 31, 2014 and 2013 and the related consolidated statements of operations, consolidated statements of changes in stockholders' equity (deficit) and consolidated statements of cash flows of Vandalia for the years ended December 31, 2014 and 2013 and the related notes and the unaudited consolidated balance sheet of Vandalia as of June 30, 2015 and the related consolidated statement of operations and consolidated statement of cash flows of Vandalia for the six months ended June 30, 2015 and 2014 and the related notes are being filed as Exhibit 99.1 to this Current Report on Form 8-K/A.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined statement of operations for the Company and Vandalia for the fiscal year ended September 30, 2014, and unaudited pro forma condensed combined balance sheet for the Company and Vandalia as of June 30, 2015 and the unaudited condensed combined statement of operations for the nine months ended June 30, 2015 are being furnished as Exhibit 99.2 to this Current Report on Form 8-K/A. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014.
- 2 - |
(d) Exhibits
2.1* |
Asset Purchase Agreement dated September 11, 2015 by and among Applied DNA Sciences, Inc., Vandalia Research, Inc. and Derek A. Gregg. |
99.1 | Audited Financial Statements of Vandalia Research, Inc. and Subsidiary as of and for the years ended December 31, 2014 and 2013 and Unaudited Financial Statements of Vandalia Research, Inc. and Subsidiary as of June 30, 2015 and for the six months ended June 30, 2015 and 2014. |
99.2 | Unaudited Pro Forma Consolidated Statement of Operations for Applied DNA Sciences, Inc. and Vandalia Research, Inc. for the fiscal year ended September 30, 2014 and nine months ended June 30, 2015, and unaudited Pro Forma Consolidated Balance Sheet for Applied DNA Sciences, Inc. and Vandalia Research, Inc. as of June 30, 2015. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014. |
* Previously filed
- 3 - |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 22, 2016 | APPLIED DNA SCIENCES, INC. | |
By: | /s/ James A. Hayward | |
Name: | James A. Hayward | |
Title: | Chief Executive Officer |
- 4 - |
Exhibit 99.1
VANDALIA RESEARCH, INC. AND SUBSIDIARY
CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 AND 2014 (UNAUDITED)
VANDALIA RESEARCH,INC. AND SUBSIDIARY
CONTENTS
Independent Auditors’ Report | 1 |
Consolidated Financial Statements | |
Balance Sheets | 2 |
Statements of Operations | 3 |
Statements of Changes in Stockholders’ Equity | 4 |
Statements of Cash Flows | 5 |
Notes to Consolidated Financial Statements | 6-20 |
INDEPENDENT AUDITORS’ REPORT
To the Board of Directors and Stockholders of
Vandalia Research, Inc. and Subsidiary
Report on the Financial Statements
We have audited the accompanying financial statements of Vandalia Research, Inc. and Subsidiary (the “Company”), which comprise the consolidated balance sheets as of December 31, 2014 and 2013, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the years then ended, and the related notes to the financial statements.
Management’s Responsibility for the Financial Statements
Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.
Auditors’ Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Vandalia Research, Inc. and Subsidiary as of December 31, 2014 and 2013, and the consolidated results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.
Melville, NY
July 22, 2016
1 |
VANDALIA RESEARCH, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
December 31, | December 31, | June 30, | ||||||||||
2014 | 2013 | 2015 | ||||||||||
(unaudited) | ||||||||||||
ASSETS | ||||||||||||
Current assets: | ||||||||||||
Cash and cash equivalents | $ | 62,851 | $ | 75,087 | $ | 25,934 | ||||||
Accounts receivable, net of allowance | 142,339 | 180,523 | 184,518 | |||||||||
Inventories | 238,234 | 155,015 | 103,199 | |||||||||
Deferred tax asset | - | - | 558,256 | |||||||||
Prepaid expenses and other current assets | 2,727 | 7,172 | 2,727 | |||||||||
Total current assets | 446,151 | 417,797 | 874,634 | |||||||||
Property, and equipment-net of accumulated depreciation of $227,726, $213,179, and $233,870 (unaudited) at December 31, 2014, 2013 and June 30, 2015, respectively | 44,807 | 33,619 | 38,663 | |||||||||
Other assets: | ||||||||||||
Deposits | 10,000 | 10,000 | 10,000 | |||||||||
Total Assets | $ | 500,958 | $ | 461,416 | $ | 923,297 | ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable and accrued liabilities | $ | 207,507 | $ | 318,794 | $ | 291,596 | ||||||
Line of credit | 157,945 | 156,213 | 157,908 | |||||||||
Current portion of related party term loan | - | - | 2,859 | |||||||||
Total current liabilities | 365,452 | 475,007 | 452,363 | |||||||||
Related party term loan, including accrued interest expense | 26,041 | 25,106 | 23,913 | |||||||||
Total Liabilities | $ | 391,493 | $ | 500,113 | $ | 476,276 | ||||||
Commitments and Contingencies | ||||||||||||
Stockholders' Equity (Deficit) | ||||||||||||
Preferred stock, par value $0.01 per share; 112,528 shares authorized, issued and outstanding as of December 31, 2014, 2013 and June 30, 2015 (unaudited) | 1,125 | 1,125 | 1,125 | |||||||||
Common stock, par value $0.01 per share; 414,472 shares authorized; 254,100 issued and outstanding as of December 31, 2014, 2013 and June 30, 2015 (unaudited) | 2,541 | 2,541 | 2,541 | |||||||||
Additional paid in capital | 2,574,086 | 2,567,215 | 2,577,522 | |||||||||
Accumulated deficit | (2,591,475 | ) | (2,730,633 | ) | (2,261,572 | ) | ||||||
Total stockholders' equity (deficit), attributable to Vandalia Research, Inc. | (13,723 | ) | (159,752 | ) | 319,616 | |||||||
Noncontrolling interest | 123,188 | 121,055 | 127,405 | |||||||||
Total stockholders' equity (deficit) | 109,465 | (38,697 | ) | 447,021 | ||||||||
Total Liabilities and Stockholders' Equity (Deficit) | $ | 500,958 | $ | 461,416 | $ | 923,297 |
See the accompanying notes to the consolidated financial statements
2 |
VANDALIA RESEARCH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
Year ended December 31, | Six Months Ended | |||||||||||||||
2014 | 2013 | June 30, 2015 | June 30, 2014 | |||||||||||||
(unaudited) | (unaudited) | |||||||||||||||
Net Sales | $ | 950,603 | $ | 740,522 | $ | 223,154 | $ | 521,175 | ||||||||
Cost of Sales | 361,659 | 453,580 | 266,637 | 245,206 | ||||||||||||
Gross Margin | 588,944 | 286,942 | (43,483 | ) | 275,969 | |||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 416,244 | 708,851 | 163,907 | 215,351 | ||||||||||||
Depreciation and amortization | 14,546 | 10,706 | 6,144 | 5,353 | ||||||||||||
Total operating expenses | 430,790 | 719,557 | 170,051 | 220,704 | ||||||||||||
INCOME (LOSS) FROM OPERATIONS | 158,154 | (432,615 | ) | (213,534 | ) | 55,265 | ||||||||||
Other income (expense): | ||||||||||||||||
Other income | - | 18,220 | - | - | ||||||||||||
Interest expense, net | (16,863 | ) | (4,616 | ) | (10,602 | ) | (7,078 | ) | ||||||||
Net Income (loss) before provision for income taxes | 141,291 | (419,011 | ) | (224,136 | ) | 48,187 | ||||||||||
Income tax benefit | - | - | (558,256 | ) | - | |||||||||||
NET INCOME (LOSS) | 141,291 | (419,011 | ) | 334,120 | 48,187 | |||||||||||
Income (Loss) attributable to noncontrolling interest | 2,133 | (13,931 | ) | 4,217 | 2,313 | |||||||||||
Net Income (loss) attributable to Vandalia Research, Inc. | $ | 139,158 | $ | (405,080 | ) | $ | 329,903 | $ | 45,874 |
See the accompanying notes to the consolidated financial statements
3 |
VANDALIA RESEARCH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CHANGES IN STOCHOLDERS' EQUITY (DEFICIT)
Preferred | Preferred Stock | Common | Common Stock | Additional Paid in | Accumulated | Non- controlling | Total | |||||||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Total | interest | Equity | ||||||||||||||||||||||||||||
Balance, January 1, 2013 | 112,528 | $ | 1,125 | 254,100 | $ | 2,541 | $ | 2,556,332 | $ | (2,325,553 | ) | $ | 234,445 | 134,986 | $ | 369,431 | ||||||||||||||||||||
Stock based compensation | - | - | - | - | 10,883 | - | 10,883 | - | 10,883 | |||||||||||||||||||||||||||
Net loss | - | - | - | - | - | (405,080 | ) | (405,080 | ) | (13,931 | ) | (419,011 | ) | |||||||||||||||||||||||
Balance, December 31, 2013 | 112,528 | 1,125 | 254,100 | 2,541 | 2,567,215 | (2,730,633 | ) | (159,752 | ) | 121,055 | (38,697 | ) | ||||||||||||||||||||||||
Stock based compensation | - | - | - | - | 6,871 | - | 6,871 | - | 6,871 | |||||||||||||||||||||||||||
Net income | - | - | - | - | - | 139,158 | 139,158 | 2,133 | 141,291 | |||||||||||||||||||||||||||
Balance, December 31, 2014 | 112,528 | 1,125 | 254,100 | 2,541 | 2,574,086 | (2,591,475 | ) | (13,723 | ) | 123,188 | 109,465 | |||||||||||||||||||||||||
Stock based compensation | - | - | - | - | 3,436 | - | 3,436 | - | 3,436 | |||||||||||||||||||||||||||
Net income | - | - | - | - | - | 329,903 | 329,903 | 4,217 | 334,120 | |||||||||||||||||||||||||||
Balance, June 30, 2015 (unaudited) | 112,528 | $ | 1,125 | 254,100 | $ | 2,541 | $ | 2,577,522 | $ | (2,261,572 | ) | $ | 319,616 | $ | 127,405 | $ | 447,021 |
See the accompanying notes to the consolidated financial statements
4 |
VANDALIA RESEARCH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASHFLOWS
Year ended December 31, | Six months ended June 30, | |||||||||||||||
2014 | 2013 | 2015 | 2014 | |||||||||||||
(unaudited) | ||||||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Net income (loss) | $ | 141,291 | $ | (419,011 | ) | $ | 334,120 | $ | 48,187 | |||||||
Adjustments to reconcile net income (loss) to net used in operating activities: | ||||||||||||||||
Depreciation and amortization | 14,546 | 10,706 | 6,144 | 5,353 | ||||||||||||
Deferred tax benefit | - | - | (558,256 | ) | - | |||||||||||
Stock based compensation expense | 6,871 | 10,883 | 3,436 | 3,436 | ||||||||||||
Interest paid in kind on term loan | 935 | 731 | 418 | |||||||||||||
Change in operating assets and liabilities: | ||||||||||||||||
Accounts receivable | 38,184 | 157,771 | (42,179 | ) | (4,943 | ) | ||||||||||
Prepaid expenses | 4,446 | (5,349 | ) | - | 5,846 | |||||||||||
Inventories | (83,219 | ) | 5,276 | 135,035 | (58,456 | ) | ||||||||||
Security deposit | - | 6,000 | - | - | ||||||||||||
Accounts payable and accrued liabilities | (111,287 | ) | 162,124 | 84,089 | 29,321 | |||||||||||
Net cash provided by (used in) operating activities | 11,767 | (71,600 | ) | (36,880 | ) | 29,162 | ||||||||||
Cash flows from investing activities: | ||||||||||||||||
Purchase of property and equipment | (25,734 | ) | (29,785 | ) | - | (25,734 | ) | |||||||||
Net cash used in investing activities | (25,734 | ) | (29,785 | ) | - | (25,734 | ) | |||||||||
Cash flows from financing activities: | ||||||||||||||||
Repayment of term loan | - | (23,377 | ) | - | - | |||||||||||
Net proceeds (repayments) lines of credit | 1,731 | 23,350 | (37 | ) | 35,708 | |||||||||||
Net cash provided by (used in) financing activities | 1,731 | (27 | ) | (37 | ) | 35,708 | ||||||||||
Net (decrease) increase in cash and cash equivalents | (12,236 | ) | (101,412 | ) | (36,917 | ) | 39,136 | |||||||||
Cash and cash equivalents at beginning of period | 75,087 | 176,499 | 62,851 | 75,087 | ||||||||||||
Cash and cash equivalents at end of period | $ | 62,851 | $ | 75,087 | $ | 25,934 | $ | 114,223 | ||||||||
Supplemental Disclosures of Cash Flow Information: | ||||||||||||||||
Cash paid during period for interest | $ | 15,928 | $ | 4,616 | $ | 9,871 | $ | 6,455 |
See the accompanying notes to the consolidated financial statements
5 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 1 - Summary of Significant Accounting Policies
Nature of Business
Vandalia Research, Inc. (“Vandalia”) was incorporated in West Virginia on September 9, 2005. Vandalia owns approximately 89% of Crosscutting Concepts, LLC ("Crosscutting") and is deemed to have a controlling interest in Crosscutting. Vandalia and its majority owned subsidiary, Crosscutting are referred to herein as the “Company”. The Company primarily engages in the production of specific high-quality DNA sequences as well as the production of educational scientific kits. The Company sells its products primarily in the United States.
Principles of Consolidation and Basis of Presentation
The consolidated financial statements include the accounts of Vandalia and its majority owned subsidiary, Crosscutting. All intercompany accounts and transactions have been eliminated upon consolidation.
Cash and Cash Equivalents
For the purposes of the statement of cash flows, the Company considers all short-term investments with an original maturity of three months or less to be cash equivalents.
In addition, the Company places its cash deposits and temporary cash investments with financial institutions that at times may be uninsured or in deposit accounts that exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit.
Allowance for Doubtful Accounts
The allowance for doubtful accounts reflects management's best estimate of probable losses inherent in the accounts receivable balance. Management determines the allowance based on known troubled accounts, historical experience, and other currently available evidence.
Inventories
Inventories, which consist primarily of raw materials, work in process, and finished goods (see Note 2), is stated at the lower of cost or market, with cost determined by using the first-in, first-out (FIFO) method.
6 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 1 - Summary of Significant Accounting Policies (continued)
Property and Equipment
Property and equipment are stated at cost. Maintenance and repairs are charged to expense as incurred; costs of major additions and betterments are capitalized. When property and equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in the statement of operations.
Depreciation
Depreciation is provided for using the straight-line method over the estimated useful lives of the related assets.
Revenue Recognition
The Company primarily derives revenue from the sales of DNA sequences and science kits to its various customers. The Company recognizes product sales revenue when title and risk of loss have transferred to the customer, there is persuasive evidence of an arrangement, shipment and passage of title has occurred, the sales price is fixed or determinable and collectability is reasonably assured.
Revenue from government contract awards, which supports the Company's development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of $92,925 during the year ended December 31, 2013. There was no grant revenue recognized during the year ended December 31, 2014 or the six months ended June 30, 2015 and 2014. In addition, the Company received $18,220 during the year ended December 31, 2013 as a grant for the purchase of an analytical system, which is included in other income on the consolidated statements of operations.
7 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 1 - Summary of Significant Accounting Policies (continued)
Use of Estimates in the Financial Statements
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from those estimates. The most significant estimates include: inventory valuation and income taxes.
Long-Lived Assets
The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Stock Based Compensation
The Company accounts for stock-based compensation for employees utilizing a fair value methodology. The fair value methodology requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the fair value methodology, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee's requisite service period (generally the vesting period of the equity grant). The fair value of the Company's common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method.
The Company recorded stock based compensation expense of $6,871, $10,883, $3,436 (unaudited) and $3,436 (unaudited) for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 and 2014, respectively. There were 1,912 and 1,237 (unaudited) unvested options as of December 31, 2014 and June 30, 2015, respectively.
8 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 1 - Summary of Significant Accounting Policies (continued)
Advertising Costs
The Company follows the policy of charging the costs of advertising to expense as incurred. Advertising costs for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 and 2014 were $2,427, $24,341, $104 (unaudited) and $2,428 (unaudited), respectively.
Shipping and Handling Costs
The Company incurs shipping and handling costs in its operations. The shipping and handling costs incurred by the Company and billed to its customers was insignificant for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 and 2014. The Company’s shipping and handling costs are included in cost of sales in the accompanying consolidated statements of operations.
Income Taxes
The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740-10”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but not limited to, equity based compensation and depreciation. The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax asset will not be realized. The accounting for uncertainty in income taxes prescribes a recognition threshold and measurement of a tax position taken or expected to be taken in an income tax return. It also provides guidance in de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. The Company recognizes such tax benefits based upon the tax position being more-likely-than-not to be sustained upon examination by taxing authorities.
The Company’s policy for recording interest and penalties is to record such items as a component of income before income taxes. Penalties are recorded in general and administrative expenses and interest paid or received is recorded in interest expense or interest income, respectively, in the statement of operations. There were no amounts accrued for penalties or interest as of or during years ended December 31, 2014 and 2013 or as of or during the six months ended June 30, 2015 and 2014. The Company does not expect its unrecognized tax benefit position to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.
9 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 1 - Summary of Significant Accounting Policies (continued)
Income Taxes (continued)
The Company has identified its Federal tax return and its State tax return in West Virginia as “major” tax jurisdictions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company’s evaluation was performed for tax years ended 2012 through 2014, the only periods subject to examination.
Subsequent Events
The Company has evaluated subsequent events occurring after the balance sheet date through July 22, 2016, which is the date of issuance of the financial statements.
10 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 2 - Inventories
Inventories consist of the following at December 31, 2014, 2013 and June 30, 2015:
December 31, | June 30, | |||||||||||
2014 | 2013 | 2015 (unaudited) | ||||||||||
Raw materials | $ | 195,064 | $ | 113,152 | $ | 44,786 | ||||||
Work in-process | 11,295 | 11,307 | 19,885 | |||||||||
Finished goods | 31,875 | 30,556 | 38,528 | |||||||||
Total | $ | 238,234 | $ | 155,015 | $ | 103,199 |
Note 3 - Property and Equipment
Property and equipment consists of the following at December 31, 2014, 2013 and June 30, 2015:
December 31, | June 30, | Estimated | ||||||||||||
2014 | 2013 | 2015 (unaudited) | Useful Lives | |||||||||||
Machinery and equipment | $ | 272,533 | $ | 246,798 | $ | 272,533 | 3 years | |||||||
Less: accumulated depreciation | (227,726 | ) | (213,179 | ) | (233,870 | ) | ||||||||
Property and Equipment, Net | $ | 44,807 | $ | 33,619 | $ | 38,663 |
Depreciation expense for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 and 2014 were $14,546, $10,706, $6,144 (unaudited) and $5,353 (unaudited), respectively.
11 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 4 - Lines of Credit
Vandalia had entered into a $100,000 line of credit agreement with a bank. Borrowings under the line of credit agreement bear interest at the Prime Rate plus 1.0%. The interest rate at December 31, 2014, 2013 and June 30, 2015 (unaudited) was 4.25%. The line of credit is due on demand. The borrowings under the line of credit are secured by substantially all assets of Vandalia. The Company had an outstanding balance of $99,323, $96,445 and $99,312 (unaudited) under the line of credit as of December 31, 2014, 2013 and June 30, 2015, respectively. This line was paid in full on September 11, 2015 with a portion of the funds received from the asset purchase agreement with Applied DNA Sciences, Inc., detailed in Note 12.
Crosscutting has a $100,000 line of credit agreement with a bank. Borrowings under the line of credit agreement bear interest at the Prime Rate plus 2.0%. The interest rate at December 31, 2014, 2013 and June 30, 2015 (unaudited) was 5.25%. The borrowings under the line of credit are secured by substantially all assets of Crosscutting. This loan was renewed on October 3, 2015 and matures on October 3, 2016. The Company had an outstanding balance of $58,622, $59,768 and $58,596 (unaudited) under the line of credit as of December 31, 2014 and 2013 and June 30, 2015, respectively.
Note 5 - Related Party Term Loan
On December 11, 2012, the Company entered into a term loan with the spouse of a shareholder of the Company for $25,000. The term loan bears interest at a rate of 5.0% and expires on December 1, 2019. Payments for principal and interest are due commencing on March 1, 2016 and payable in quarterly installments of $1,734, thereafter until maturity. Accrued interest on this loan as of December 31, 2014, 2013 and June 30, 2015 was $1,041, $106 and $1,772 (unaudited), respectively and is included in the term loan balance on the accompanying consolidated balance sheet.
Future minimum principal maturities under this debt agreement are as follows:
For the Year Ended December 31, | Amount | |||
2015 | $ | — | ||
2016 | 5,790 | |||
2017 | 6,088 | |||
2018 | 6,398 | |||
2019 | 6,724 | |||
Total | $ | 25,000 |
12 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 6 - Stockholders’ Equity
Common and Preferred Stock
The Company has both common and preferred stock. The preferred stockholders are entitled to dividends at a rate of 8.0% of the original purchase price, per year. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, as defined, the preferred stockholders also have the right to be paid out in full before any payment shall be made to the common stockholders. The preferred stock is convertible, at the option of the holder, into shares of the Company's common stock at the initial preferred stock conversion price of $13.33, subject to adjustment, as defined per the agreement.
Note 7 - Income Taxes
The provision for income taxes included for the years ended December 31, 2014 and 2013 consists of the following:
2014 | 2013 | |||||||
Current: | ||||||||
Federal | $ | — | $ | — | ||||
State and Local | — | — | ||||||
Total Current | — | — | ||||||
Deferred: | ||||||||
Federal | (52,562 | ) | 136,332 | |||||
State and Local | (6,336 | ) | 16,457 | |||||
Change in valuation allowance | 58,898 | (152,789 | ) | |||||
Total Deferred | - | - | ||||||
Total | $ | — | $ | — |
13 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 7 - Income Taxes (continued)
The provision for income taxes included for the six months ended June 30, 2015 and 2014(unaudited) consists of the following:
2015 | 2014 | |||||||
Current: | ||||||||
Federal | $ | — | $ | — | ||||
State and Local | — | — | ||||||
Total Current | — | — | ||||||
Deferred: | ||||||||
Federal | (76, 992 | ) | (11,004 | ) | ||||
State and Local | (9,294 | ) | (1,328 | ) | ||||
Change in valuation allowance | (471,970 | ) | 12,332 | |||||
Total Deferred | (558,256 | ) | - | |||||
Total | $ | (558,256 | ) | $ | - |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is required if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of December 31, 2014 and 2013, based on current income projections, management concluded that it is more likely than not that the Company will not realize any benefits from the deferred tax assets recorded by the Company in previous periods. As of June 30, 2015, based on the sale of the assets in September 2015 as disclosed in Note 12, management concluded that it is more likely than not that the Company will utilize certain of its net operating losses and as such reduced its deferred tax valuation allowance by $471,970.
14 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 7 - Income Taxes (continued)
The tax effects of temporary differences that give rise to significant portions of the deferred tax assets at December 31, 2014 and 2013 and June 30, 2015 are presented as follows:
December 31, | June 30, | |||||||||||
2014 | 2013 | 2015 | ||||||||||
Deferred tax assets, current | (unaudited) | |||||||||||
Allowance for doubtful accounts | $ | 79 | $ | 79 | $ | 79 | ||||||
Net operating loss carryforwards | — | — | 558,256 | |||||||||
Total Deferred Tax Assets, current | 79 | 79 | 558,335 | |||||||||
Deferred tax assets, long-term | ||||||||||||
Net operating loss carryforwards | 952,644 | 1,006,908 | 482,313 | |||||||||
Investment in subsidiary | 42,252 | 45,576 | 39,083 | |||||||||
Total Long-Term Deferred Tax Assets | 994,896 | 1,052,484 | 1,079,731 | |||||||||
Deferred tax liabilities, long-term | ||||||||||||
Property and equipment | (9,242 | ) | (7,932 | ) | (7,712 | ) | ||||||
Net Deferred Tax Assets | 985,733 | 1,044, 631 | 1,072,019 | |||||||||
Less: valuation allowance | (985,733 | ) | (1,044,631 | ) | (513,763 | ) | ||||||
Total Net Deferred Tax Assets | $ | — | $ | — | 558,256 |
At December 31, 2014 and June 30, 2015, the Company has net operating losses of approximately $2,428,667 and $2,652,821 (unaudited) expiring at various dates through 2035.
15 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 8 - Commitments and Contingencies
Litigation
From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.
Lease Agreements
The Company has a lease commitment under a non-cancelable operating lease which expired in November 2014, principally for equipment and facilities and was on a month to month status until March 1, 2015. On March 1, 2015, the Company entered into a lease agreement with annual rent of $93,600. The Company has two subleases for a portion of its facility. The one sublease was from September 1, 2011 and expired on August 31, 2013. The other sublease commenced during October 2009 and is on a month to month basis.
Future minimum lease payments under these operating leases are as follows:
For the Year Ending December 31, | Amount | |||
2015 | $ | 78,000 | ||
2016 | 15,600 | |||
Total | $ | 93,600 |
16 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 8 - Commitments and Contingencies (continued)
Lease Agreements (Continued)
Rent expense, net with sublease rental income for the years ended December 31, 2014, 2013 and the six months ended June 30, 2015 was $57,050, 52,077 and $28,600 (unaudited), respectively. Sublease rental income for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 was $18,900, $28,100 and $6,500 (unaudited), respectively.
License Agreement
Vandalia has a patent license agreement with Marshall University Research Corporation (“Marshall”), a related party, that was entered into during August 2005 and subsequently amended on April 15, 2008. In consideration for the license, Marshall was issued 5% of the common stock of Vandalia, in addition, Vandalia pays Marshall 1% of the net revenues received by Vandalia, as defined in the agreement.
Commencing December 31, 2010, Vandalia shall pay the greater of the royalty payable, or $10,000 per year. The term of this agreement was for five years, with an automatic renewal for an additional five years. The license fees incurred for the years ended December 31, 2014 and 2013 and for the six months ended June 30, 2015 were $10,000, $10,640 and $10,000 (unaudited), respectively. The amounts due to Marshall as of December 31, 2014, 2013 and June 30, 2015 were $14,640, $10,640, and $24,640 (unaudited), respectively and is included in accounts payable and accrued liabilities in the consolidated balance sheets.
Note 9 - Stock Option Plans
The Company currently has stock options outstanding related to the 2010 Long Term Incentive Plan (the “2010 Plan”), which allows the Company to grant options to purchase common stock to employees of the Company. Under the 2010 Plan, options have a ten year term and vest twenty-five percent immediately and the remainder vest evenly over a three year period. The 2010 Plan expired on June 1, 2012 and there will be no further issuances under the 2010 Plan. As of December 31, 2014, unrecorded compensation expense related to non-vested awards was $9,732, which is expected to be recognized over a weighted average period of approximately 1.42 years. As of June 30, 2015, unrecorded compensation expense related to non-vested awards was $6,296 (unaudited), which is expected to be recognized over a weighted average period of approximately 0.92 (unaudited) years.
17 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 9 - Stock Option Plans (continued)
As of December 31, 2014 and June 30, 2015, the, weighted average remaining contractual life of these options was 8.42, and 7.92 (unaudited) years, respectively. There were 5,400 options granted during the year ended December 31, 2013 and no options were granted during the year ended December 31, 2014 or the six months ended June 30, 2015. There were no cancellations of options during 2014 and 2013 or during the six months ended June 30, 2015. The weighted average grant date fair value per share for options granted during the year ended December 31, 2013 was $5.09.
Transactions involving stock options issued to employees are summarized below:
Number of Shares | Weighted Average Exercise Price Per Share | |||||||
Outstanding at January 1, 2014 | 5,400 | $ | 6.00 | |||||
Granted | — | — | ||||||
Exercised | — | — | ||||||
Cancelled or expired | — | — | ||||||
Outstanding at December 31, 2014 | 5,400 | $ | 6.00 | |||||
Granted (unaudited) | — | — | ||||||
Exercised (unaudited) | — | — | ||||||
Cancelled or expired (unaudited) | — | — | ||||||
Outstanding at June 30, 2015 (unaudited) | 5,400 | $ | 6.00 | |||||
Vested at December 31, 2014 | 3,488 | $ | 6.00 | |||||
Non-vested at December 31, 2014 | 1,912 | |||||||
Vested at June 30, 2015 (unaudited) | 4,163 | $ | 6.00 | |||||
Non-vested at June 30, 2015 (unaudited) | 1,237 |
The fair value of options granted to employees during the year ended December 31, 2013 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:
Stock price | $ | 6.00 | ||
Exercise price | $ | 6.00 | ||
Expected term, years | 5.75 | |||
Dividend yield | — | % | ||
Volatility | 157 | % | ||
Risk free rate | 1.05 | % |
18 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 9 - Stock Option Plans (continued)
The stock price was determined based on management's estimate. As the Company has been privately held since inception, there is no specific historical or implied volatility information available. Accordingly, the Company determines volatility based on an average of reported volatility of selected peer companies within the industry.
Note 10 - Concentration of Credit Risk
During the years ended December 31, 2014 and 2013, sales to two and four customers, totaled $623,358 (66%) and $460,536 (62%), respectively. As of December 31, 2014 and 2013, the amount due from these customers included in accounts receivable was $0 and $119,033, respectively. During the six months ended June 30, 2015 and 2014, sales to three and two customers, totaled $113,791 (51%) and $343,358 (66%)(unaudited). As of June 30, 2015 the amount due from these customers included in accounts receivable was $57,777 (unaudited).
During the years ended December 31, 2014 and 2013, the Company purchased a substantial portion of its inventory from one supplier. Inventory purchases from this supplier totaled $108,765 (47%) and $55,642 (24%), respectively. As of December 31, 2014 and 2013, the amount due to this supplier was $0 and $33,568, respectively.
Note 11 - Related Party Transactions
The spouse of the Company's Chief Executive Officer provided accounting services for the Company. The total expense recorded for these services was $8,778, $5,982, $5,687 (unaudited) and $3,861(unaudited), respectively for the years ended December 31, 2014 and 2013 and the six months ended June 30, 2015 and 2014.
19 |
VANDALIA RESEARCH, INC. AND SUBSIDIAIRES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS
ENDED DECEMBER 31, 2014 AND 2013 AND THE SIX MONTHS ENDED JUNE 30, 2015 (unaudited) |
Note 12 - Subsequent Events
On September 11, 2015, Vandalia entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Applied DNA Sciences, Inc., providing for the sale of substantially all the assets (“Assets”) of Vandalia. The Vandalia Assets sold relate to the business of producing specific, high-quality DNA sequences with the PCR production system known as Triathlon™ , including machinery, equipment, inventory, registered and other intellectual property, including patents, trademarks, trade secrets, domain names, copyrights and rights to software, and customer contracts. The Assets also include Vandalia’s rights under a patent license agreement between Marshall University Research Corporation (“Marshall”) and Vandalia. The purchase price for the Assets was $1,500,000, which amount was determined through arms-length negotiation. Of this amount, $500,000 was placed in an escrow account for a period of nine (9) months following the closing to satisfy Vandalia’s indemnification obligations with $350,000 of this amount less the amount of any indemnification claims paid out of escrow to be released after sixty (60) days. Vandalia and Derek Gregg, Vandalia's chief executive officer, agreed not to compete with Applied DNA Sciences, Inc. and not to solicit its employees or customers for a period of five (5) years following the closing. Derek Gregg also entered into a consulting agreement with Applied DNA Sciences, Inc. for a term of twelve (12) months subject to earlier termination by either party upon thirty (30) days’ notice. Pursuant to the Asset Purchase Agreement, Applied DNA Sciences, Inc., entered into a month to month sublease with Vandalia of approximately 5,000 square feet at Vandalia’s office facility at an aggregate monthly rent of $5,416. Purchase orders of $237,000 were assigned by Vandalia to Applied DNA Sciences, Inc.. Prior to the Vandalia Asset Acquisition, Applied DNA Sciences, Inc. was a customer of Vandalia.
20 |
Exhibit 99.2
UNAUDITED PRO FORMA FINANCIAL INFORMATION
The following unaudited pro forma financial statements give effect to the Asset Purchase Agreement (the “Asset Purchase Agreement”), dated September 11, 2015, by and among Applied DNA Sciences, Inc. (the “Company” or “APDN”), Vandalia Research, Inc., a West Virginia corporation (now known as VR Holdings, Inc., “Vandalia”), and Derek A. Gregg, Vandalia’s Chief Executive Officer and a director of Vandalia, providing for the purchase by the Company of substantially all the assets of Vandalia (the “Asset Acquisition”) under the acquisition method of accounting in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Topic 805, Business Combinations (“ASC 805”), with the Company treated as the legal and accounting acquirer. The historical consolidated financial information has been adjusted in the unaudited pro forma financial statements to give effect to pro forma events that are (1) directly attributable to the Asset Acquisition, (2) factually supportable, and (3) with respect to the statements of operations, have a continuing impact on the combined results of the Company and Vandalia. The unaudited pro forma condensed combined balance sheet is based on the individual historical balance sheets of the Company and Vandalia as of June 30, 2015, and has been prepared to reflect the Asset Acquisition as if it occurred on June 30, 2015. The unaudited pro forma condensed combined statements of operations for the fiscal year ended September 30, 2014 and the nine months ended June 30, 2015 are based on the historical results of operations of the Company and Vandalia, giving effect to the Asset Acquisition as if it occurred on October 1, 2013. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014.
The unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of: (i) results of operations and financial position that would have been achieved had the Asset Acquisition taken place on the dates indicated or (ii) the future results of operations or financial position of the Company following the Asset Acquisition. All pro forma adjustments and their underlying assumptions are described more fully in the notes to the unaudited pro forma condensed combined financial information. Actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.
1 |
CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Year Ended September 30, 2014
Historical | ||||||||||||||||||||||
APDN | Vandalia | Total Historical | Pro
Forma For
The (Note 3) | Footnote Reference (Note 3) | Pro Forma Combined | |||||||||||||||||
Year Ended September
30, | Year Ended December
31, | |||||||||||||||||||||
Revenues | $ | 2,721,224 | $ | 950,603 | 3,671,827 | $ | (548,506 | ) | A, D | $ | 3,123,321 | |||||||||||
Cost of goods sold | - | 361,659 | 361,659 | (142,461 | ) | A | 219,198 | |||||||||||||||
Gross profit | 2,721,224 | 588,944 | 3,310,168 | (406,045 | ) | 2,904,123 | ||||||||||||||||
Selling, general and administrative expenses | 13,249,753 | 416,244 | 13,665,997 | (146,596 | ) | A, E | 13,519,401 | |||||||||||||||
Research and development | 1,300,750 | - | 1,300,750 | (275,653 | ) | D | 1,025,097 | |||||||||||||||
Depreciation and amortization | 442,262 | 14,546 | 456,808 | 89,624 | A, B | 546,432 | ||||||||||||||||
Total operating expenses | 14,992,765 | 430,790 | 15,423,555 | (332,625 | ) | 15,090,930 | ||||||||||||||||
(Loss) income from operations | (12,271,541 | ) | 158,154 | (12,113,387 | ) | (73,420 | ) | (12,186,807 | ) | |||||||||||||
Other income (expense): | ||||||||||||||||||||||
Interest expense, net | (11,029 | ) | (16,863 | ) | (27,892 | ) | 16,863 | A | (11,029 | ) | ||||||||||||
Other income | 123,914 | - | 123,914 | - | 123,914 | |||||||||||||||||
Loss on conversion of promissory notes | (908,005 | ) | - | (908,005 | ) | - | (908,005 | ) | ||||||||||||||
Loss before provision for income taxes | (13,066,661 | ) | 141,291 | (12,925,370 | ) | (56,557 | ) | (12,981,927 | ) | |||||||||||||
Income taxes (benefit) | - | - | - | - | - | |||||||||||||||||
Net (loss) income | $ | (13,066,661 | ) | $ | 141,291 | $ | (12,925,370 | ) | $ | (56,557 | ) | $ | (12,981,927 | ) | ||||||||
Income attributable to noncontrolling interest | $ | - | $ | 2,133 | $ | 2,133 | $ | (2,133 | ) | A | $ | - | ||||||||||
Income attributable to Vandalia Research, Inc. | $ | - | $ | 139,158 | $ | 139,158 | $ | (139,158 | ) | A | $ | - | ||||||||||
Net loss per share - basic and diluted | $ | (0.97 | ) | $ | - | $ | - | $ | - | $ | (0.96 | ) | ||||||||||
Weighted-average shares outstanding -basic and diluted | 13,515,518 | - | - | - | 13,515,518 |
See accompanying notes to unaudited pro forma condensed combined financial information
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
For the Nine Months Ended June 30, 2015
Historical | ||||||||||||||||||||||
APDN | Vandalia | Total Historical | Pro
Forma For
The (Note 3) | Footnote Reference (Note 3) | Pro Forma Combined | |||||||||||||||||
Revenues | $ | 5,028,234 | $ | 407,010 | $ | 5,435,244 | $ | (203,083 | ) | A | $ | 5,232,161 | ||||||||||
Cost of goods sold | - | 353,762 | 353,762 | (105,267 | ) | A | 248,495 | |||||||||||||||
Gross profit | 5,028,234 | 53,248 | 5,081,482 | (97,816 | ) | 4,983,666 | ||||||||||||||||
Selling, general and administrative expenses | 11,078,405 | 288,907 | 11,367,312 | (113,454 | ) | A, F | 11,253,858 | |||||||||||||||
Research and development | 961,745 | - | 961,745 | - | 961,745 | |||||||||||||||||
Depreciation and amortization | 354,144 | 9,781 | 363,925 | 68,347 | A, C | 432,272 | ||||||||||||||||
Total operating expenses | 12,394,294 | 298,688 | 12,692,982 | (45,107 | ) | 12,647,875 | ||||||||||||||||
Loss from operations | (7,366,060 | ) | (245,440 | ) | (7,611,500 | ) | (52,709 | ) | (7,644,209 | ) | ||||||||||||
Other income (expense) | ||||||||||||||||||||||
Interest income (expense), net | (26,807 | ) | (14,426 | ) | (41,233 | ) | 14,426 | A | (26,807 | ) | ||||||||||||
Other income (expense) | (16,853 | ) | (131 | ) | (16,984 | ) | 131 | A | (16,853 | ) | ||||||||||||
Loss on conversion of promissory notes | (980,842 | ) | - | (980,842 | ) | - | (980,842 | ) | ||||||||||||||
Other income, net | (2,994,540 | ) | - | (2,994,540 | ) | - | (2,994,540 | ) | ||||||||||||||
Loss before provision for income taxes | (11,385,102 | ) | (259,997 | ) | (11,645,099 | ) | (38,152 | ) | (11,683,251 | ) | ||||||||||||
Income taxes (benefit) | - | (558,256 | ) | (558,256 | ) | 558,256 | G | - | ||||||||||||||
Net (loss) income | $ | (11,385,102 | ) | $ | 298,259 | $ | (11,086,843 | ) | (596,408 | ) | (11,683,251 | ) | ||||||||||
Income (loss) attributable to noncontrolling interest | - | 1,259 | 1,259 | (1,259 | ) | A | - | |||||||||||||||
Income (loss) attributable to Vandalia Research, Inc. | $ | - | $ | 297,000 | $ | 297,000 | $ | (297,000 | ) | A | $ | - | ||||||||||
Net loss per share - basic and diluted | $ | (0.63 | ) | $ | - | $ | - | $ | - | $ | (0.65 | ) | ||||||||||
Weighted-average shares outstanding -basic and diluted | 18,075,506 | - | - | - | 18,075,506 |
See accompanying notes to unaudited pro forma condensed combined financial information
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET
As of June 30, 2015
Historical | ||||||||||||||||||||||
APDN | Vandalia | Total Historical | Pro
Forma | Footnote | Pro
Forma | |||||||||||||||||
ASSETS | ||||||||||||||||||||||
Current assets: | ||||||||||||||||||||||
Cash and cash equivalents | $ | 10,730,144 | $ | 25,934 | $ | 10,756,078 | $ | (1,525,934 | ) | A, B | $ | 9,230,144 | ||||||||||
Accounts receivable, net | 2,077,756 | 184,518 | 2,262,274 | (184 518 ) | B | 2,077,756 | ||||||||||||||||
Inventories | - | 103,199 | 103,199 | (73,199 | ) | B | 30,000 | |||||||||||||||
Deferred tax asset | - | 558,256 | 558,256 | (558,256 | ) | A, B | - | |||||||||||||||
Prepaid expenses and other current assets | 209,831 | 2,727 | 212,558 | (2,727 | ) | A, B | 209,831 | |||||||||||||||
Total current assets | 13,017,731 | 874,634 | 13,892,365 | (2,344,634 | ) | 11,547,731 | ||||||||||||||||
Property, plant and equipment, net | 526,816 | 38,663 | 565,479 | (2,049 | ) | A | 563,430 | |||||||||||||||
Other assets: | ||||||||||||||||||||||
Deposits | 52,988 | 10,000 | 62,988 | - | 62,988 | |||||||||||||||||
Goodwill | - | - | - | 285,386 | A | 285,386 | ||||||||||||||||
Intangible assets, net | 525,902 | - | 525,902 | 1,138,000 | A | 1,663,902 | ||||||||||||||||
Total assets | $ | 14,123,437 | $ | 923,297 | $ | 15,046,734 | $ | (923,297 | ) | $ | 14,123,437 | |||||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) | ||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||
Accounts payable and accrued liabilities | $ | 1,418,615 | $ | 291,596 | $ | 1,710,211 | $ | (77,463 | ) | B, C | $ | 1,632,748 | ||||||||||
Deferred revenue | 204,863 | - | 204,863 1 | - | 204,863 | |||||||||||||||||
Lines of credit | - | 157,908 | 157,908 | (157,908 | ) | B | - | |||||||||||||||
Current portion of related party term loan | - | 2,859 | 2,859 | (2,859 | ) | B | - | |||||||||||||||
Total current liabilities | 1,623,478 | 452,363 | 2,075,841 | ( | (238,230 | ) | 1,837,611 | |||||||||||||||
Related party term loan, net of current portion | - | 23,913 | 23,913 | (23,913 | ) | B | - | |||||||||||||||
Total liabilities | 1,623,478 | 476,276 | 2,099,754 | (262,143 | ) | 1,837,611 | ||||||||||||||||
Shareholders’ equity: | ||||||||||||||||||||||
Preferred stock | - | 1,1,25 | 1,125 | (1,125 | ) | B | - | |||||||||||||||
Series A Preferred stock | - | - | - | - | - | |||||||||||||||||
Series B Preferred stock | - | - | - | - | - | |||||||||||||||||
Common stock | 21,483 | 2,541 | 24,024 | (2,541 | ) | B | 21,483 | |||||||||||||||
Additional paid in capital | 223,623,850 | 2,577,522 | 226,201,372 | (2,577,522 | ) | B | 223,623,850 | |||||||||||||||
Accumulated deficit | (211,145,374 | ) | (2,261,572 | ) | (213,406,946 | ) | 2,047,439 | B, C | (211,359,507 | ) | ||||||||||||
Noncontrolling interest | - | 127,405 | 127,405 | (127,405 | ) | B | - | |||||||||||||||
Total shareholders’ equity (deficit) attritbutable to Applied DNA Sciences, Inc. | 12,499,959 | 447,021 | 12,946,980 | (661,154 | ) | 12,285,826 | ||||||||||||||||
Total liabilities and shareholders’ equity | $ | 14,123,437 | $ | 923,297 | $ | 15,046,734 | $ | (923,297 | ) | $ | 14,123,437 |
See accompanying notes to unaudited pro forma condensed combined financial information
Notes to Unaudited Pro Forma Condensed Combined Financial Information
Note 1- Basis of presentation
The unaudited pro forma combined financial information herein is based upon the historical consolidated financial statements of APDN and Vandalia and has been prepared to illustrate the effects of the reported transactions in accordance with accounting principles generally accepted in the United States and pursuant to Article 11 of Regulation S-X.
The Asset Acquisition was accounted as a business combination using the acquisition method of accounting under the provisions of ASC 805, Business Combinations ("ASC 805"). Under ASC 805, all assets acquired are recorded at their acquisition date fair value. The allocation of the purchase price as reflected in the unaudited pro forma condensed combined financial data is based upon a third party valuation firm's valuation of the fair market value of assets acquired, as if the Asset Acquisition had occurred on June 30, 2015, with respect to the unaudited pro forma condensed combined balance sheet. With respect to the unaudited pro forma condensed combined statement of operations, the allocation of purchase price is reflected for the fiscal year ended September 30, 2014 and the nine months ended June 30, 2015, giving effect to the Asset Acquisition as if it occurred on October 1, 2013. The fiscal year ended September 30, 2014 referenced in such unaudited pro forma statement of operations is the fiscal year of the Company. Because the fiscal year of Vandalia ends on December 31 of each year, such unaudited pro forma statement of operations makes reference to the fiscal year of Vandalia ended December 31, 2014.
Note 2- Allocation of consideration transferred to the assets acquired
For the purposes of this pro forma financial information, fair values have been determined by a third party valuation firm for all assets acquired. The excess of the acquisition consideration over the fair value of the assets acquired is allocated to goodwill. The adjustments to reflect the acquisition method of accounting are based upon available information and certain assumptions which management believes are reasonable under the circumstances.
The following table summarizes the purchase price allocation as if the Asset Acquisition had occurred as of June 30, 2015:
Purchase price | $ | 1,500,000 | ||
Allocation of purchase price to the fair market values of assets acquired: | ||||
Goodwill | $ | 285,386 | ||
Identifiable intangible assets | 1,138,000 | |||
Security deposit | 10,000 | |||
Fixed assets | 36,614 | |||
Inventory | 30,000 | |||
Total | $ | 1,500,000 |
The goodwill and identifiable intangible assets related to the Acquisition are tax deductible.
Note 3- Pro Forma adjustments for the combined statement of operations
(A) | Adjustment to remove items not purchased as part of the Asset Purchase Agreement. |
(B) | Adjustment to record 12 months of identifiable intangible assets amortization of $91,966 and depreciation on fixed assets acquired of $12,204. |
(C) | Adjustment to record 9 months of identifiable intangible assets amortization of $68,975 and depreciation on fixed assets acquired of $9,153. |
(D) | Adjustment to eliminate sales of $275,653 between Vandalia and APDN during the fiscal year ended September 30, 2014. |
(E) | Adjustment to record 12 months of consulting expense per Derek Gregg's consulting agreement of $60,000 and remove his payroll expense of $101,175 for the same period. |
(F) | Adjustment to record 9 months of consulting expense per Derek Gregg's consulting agreement of $45,000 and remove his payroll expense of $78,558 for the same period. |
(G) | Adjustment to remove the deferred tax benefit for the gain on the sale of assets of $558,256. |
Note 4- Pro Forma adjustments for the combined balance sheet
(A) | Adjustment to record the purchase price consideration of $1,500,000 in cash. |
(B) | Adjustment to remove the items for not purchased as part of the Asset Purchase Agreement. |
(C) | Adjustment to accrue for transactions costs incurred as part of the Asset Purchase Agreement. |